AstraZeneca unveils second brand play in India
This article was originally published in Scrip
Executive Summary
AstraZeneca appears to be the latest to join a clutch of foreign firms deploying the second-brand approach to penetrate the Indian market more effectively.
You may also be interested in...
Asia Deal Watch: Takeda To Team Up With Protagonist On Treatment For Polycythemia Vera
Plus alliances involving Formosa/Cristalia, Renalys/Travere, Astellas/Vivtex, Zydus/Synthon, AFT/Hyloris and Astellas/Mass General Brigham hospital.
Sun Backs India-First Stroke Drug From Pharmazz
Sun debuts Pharmazz Inc’s new stroke drug sovateltide in India at under $20/ vial. The selective endothelin-B receptor agonist, which can be administered up to 24 hours post cerebral ischemic stroke, is also being studied in Alzheimer’s disease.
Eisai-Mylan Tango for Second Halaven Brand In India But Eyes On Pricing, Generics
Eisai has struck a deal with Mylan for a second brand of Halaven in India, joining a growing list of foreign firms deploying this approach to expand access to novel therapies in the country amid emerging competition.